KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2025)

Historic Operating Leases for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Q3 2025 value amounting to $42.2 million.

  • Supernus Pharmaceuticals' Operating Leases rose 1063.87% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 1063.87%. This contributed to the annual value of $34.3 million for FY2024, which is 1747.3% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Operating Leases of $42.2 million as of Q3 2025, which was up 1063.87% from $31.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Operating Leases' 5-year high stood at $56.0 million during Q1 2021, with a 5-year trough of $31.8 million in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median Operating Leases value was $42.2 million (recorded in 2025), while the average stood at $41.9 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 6331.0% in 2021, then tumbled by 2331.52% in 2025.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Operating Leases stood at $47.8 million in 2021, then decreased by 10.44% to $42.8 million in 2022, then dropped by 2.95% to $41.5 million in 2023, then dropped by 17.47% to $34.3 million in 2024, then increased by 23.17% to $42.2 million in 2025.
  • Its Operating Leases was $42.2 million in Q3 2025, compared to $31.8 million in Q2 2025 and $32.3 million in Q1 2025.